Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Eli Lilly and Company Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00191087 |
The purpose of this study is to monitor the long term safety of duloxetine in the treatment of stress urinary incontinence.
Condition | Intervention | Phase |
---|---|---|
Urinary Incontinence, Stress |
Drug: Duloxetine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety Study |
Official Title: | Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence. |
Estimated Enrollment: | 458 |
Study Start Date: | April 2001 |
Estimated Study Completion Date: | May 2006 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United Kingdom, England | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician. | |
London, England, United Kingdom, SE3 7UQ |
Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Study ID Numbers: | 2686, F1J-MC-SBAU |
Study First Received: | September 12, 2005 |
Last Updated: | January 24, 2007 |
ClinicalTrials.gov Identifier: | NCT00191087 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Signs and Symptoms Dopamine Urinary Incontinence, Stress Urologic Diseases Urination Disorders |
Stress Urinary Incontinence Serotonin Duloxetine |
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic Uptake Inhibitors Physiological Effects of Drugs Psychotropic Drugs Serotonin Uptake Inhibitors |
Pharmacologic Actions Urological Manifestations Pathologic Processes Serotonin Agents Therapeutic Uses Dopamine Agents Central Nervous System Agents Antidepressive Agents |